Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 3,600 shares, a decrease of 49.3% from the August 15th total of 7,100 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is presently 0.8 days.
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
An institutional investor recently raised its position in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC grew its holdings in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after buying an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent SEC filing. Institutional investors own 2.94% of the company's stock.
Get Calliditas Therapeutics AB (publ) alerts:Calliditas Therapeutics AB (publ) Stock Performance
Calliditas Therapeutics AB (publ) stock opened at $15.95 on Thursday. The stock has a market cap of $471.73 million, a P/E ratio of -6.40 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $18.07 and a 200-day moving average of $17.74. Calliditas Therapeutics AB has a 52 week low of $12.55 and a 52 week high of $27.50.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on CALT shares. Kepler Capital Markets started coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 16th. They issued a "buy" rating for the company. TheStreet cut Calliditas Therapeutics AB (publ) from a "c-" rating to a "d" rating in a report on Tuesday, September 6th. Finally, Pareto Securities assumed coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 2nd. They issued a "buy" rating for the company.About Calliditas Therapeutics AB (publ)
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Featured Articles
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.